primary liver cancer
Conditions
Interventions
Wuda formula granule group (Group A):Wuda formula granule plus enhanced recovery after surgery
Wuda granule group (Goup B):Wuda granule plus enhanced recovery after surgery
Wuda decoction group (Group C):Wuda decoction plus enhanced recovery after surgery
Sponsors
Guangdong Provincial Hospital of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Age: 18-70 years old; 2. History of hepatitis B or C virus infection; 3. Clinically diagnosed as primary hepatocellular carcinoma (HCC) through two or more imaging examinations such as ultrasound, CT, MR, DSA, etc. before surgery; And according to the diagnosis and treatment standards for primary liver cancer in China released by NHFPC, cases with stages Ia, Ib, and IIa are classified; 4. Child pugh A-grade liver function; 5. Patients who underwent laparoscopic liver surgery with intraoperative blood loss not exceeding 400ml, and whose hepatic hilum was blocked using the pringle method during the surgery; 6. No previous history of abdominal surgery; 7. Preoperative gastrointestinal electrogram indicates normal gastrointestinal electrical activity; 8. Failure to undergo TACE, PVE, or radiation therapy prior to surgical treatment; 9. Have not used molecular targeting, chemotherapy, or immunotherapy before surgery; 10. Exclude cases of systemic dysfunction in important systems and organs other than the liver.
Exclusion criteria
Exclusion criteria: 1. Under 18 years old and over 70 years old; 2. Postoperative paraffin pathology suggests primary intrahepatic cholangiocarcinoma (ICC) or mixed type carcinoma (HCC-ICC); 3. Cases classified as stage IIb or above according to the diagnosis and treatment standards for primary liver cancer in China released by NHFPC; 4. Cases of HCC combined with tumor rupture and bleeding; 5. Open surgery cases, or cases where bleeding exceeds 400ml during laparoscopic surgery, or cases where blood products need to be transfused during surgery; 6. Family history of genetic diseases, or cases with concomitant immune diseases; 7. Cases of postoperative severe gastrointestinal dysfunction requiring intervention measures such as gastrointestinal decompression and enema; 8. Cases where the investigational drug cannot be taken in conjunction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| time for first defecation;time for solid diet tolerance ; | — |
Secondary
| Measure | Time frame |
|---|---|
| time for first flatus;time for first bowl sounds;Incidence of postoperative ileus;Motilin;Ghrelin;IL-1ß;TNF-a;C-reactive protein;abdominal distension and nausea and vomiting; | — |
Countries
China
Contacts
Public ContactJiangzhi
Guangdong Provincial Hospital of Chinese Medicine
Outcome results
None listed